Schizophrenia News and Research

Latest Schizophrenia News and Research

MDMA produces friendliness, playfulness, and loving feelings in laboratory setting

MDMA or 'ecstasy' increases feelings of empathy and social connection. These 'empathogenic' effects suggest that MDMA might be useful to enhance the psychotherapy of people who struggle to feel connected to others, as may occur in association with autism, schizophrenia, or antisocial personality disorder.

15 Dec 2010

Access problems for psychiatric patients to Medicaid medication leads to increased hospital, emergency care

Too often, mental health patients have problems accessing or paying for their prescription drugs under Medicaid. The results — longer hospital stays and more emergency room visits — are hard on patients and costly for the entire health care system, a new study finds.

10 Dec 2010

First genetic test on developing risk of Alzheimer's disease and heart attacks

Alzheimer and heart attacks have been found to share common genetic basis. The research leads the way to the first genetic test on developing the risk of the diseases even at a young age. According to Federico Licastro, an immunologist at the University of Bologna who coordinated the study published in the scientific journal, Journal of Alzheimer's Disease, a test is now ready. "They are already selling it in America", he says, citing the case of a private firm in New Mexico (USA) that collaborated on the study. "But the tests could easily be also conducted wherever, using a simple blood test".

10 Dec 2010

Sunovion reports results of Latuda third phase 3 worldwide clinical trial for schizophrenia

Sunovion Pharmaceuticals Inc. today announced the results of the PEARL 3 study, the third phase 3 worldwide clinical trial of Latuda® (lurasidone HCl) tablets, a once-daily atypical antipsychotic agent recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with schizophrenia. In this six-week, placebo-controlled trial, both fixed doses of LATUDA 80 and 160 mg once-daily, demonstrated statistically significant improvement in symptoms of schizophrenia versus placebo across both primary and secondary efficacy measures.

9 Dec 2010

Alkermes announces preliminary results from ALKS 33 Phase 2 study in alcohol dependence

Alkermes, Inc. today announced preliminary results from a phase 2 clinical study of ALKS 33, one of Alkermes' proprietary candidates for the treatment of reward disorders and other central nervous system (CNS) disorders. The 12-week study was designed to assess the safety and efficacy of daily oral administration of three different dose levels of ALKS 33 compared to placebo in 400 alcohol dependent patients.

9 Dec 2010

Alexza Pharmaceuticals to meet with FDA to discuss CRL regarding its NDA for AZ-004

Alexza Pharmaceuticals, Inc. announced today that the Company has scheduled an End-of Review meeting with the U.S. Food and Drug Administration in December to discuss the Complete Response Letter regarding the Company's New Drug Application for AZ-004 (Staccato loxapine).

8 Dec 2010

Expansion of newborn screening throws some families on a journey of great uncertainty

Mandatory genetic screening of newborns for rare diseases is creating unexpected upheaval for families whose infants test positive for risk factors but show no immediate signs of the diseases, a new UCLA study warns.

7 Dec 2010

People suffering psychotic disorders 12 times more likely to commit suicide

People with psychotic disorders, such as schizophrenia or bipolar disorder, are 12 times more likely to commit suicide than average, according to research released today by King's Health Partners.

7 Dec 2010

Genentech announces Phase II study results of RG1678 for treatment of schizophrenia

Genentech, Inc., a member of the Roche Group, today announced eight-week results from a Phase II study of RG1678, its investigational first-in-class glycine reuptake inhibitor for the treatment of schizophrenia.

6 Dec 2010

Lundbeck reports positive phase III study data of clobazam in treating seizures associated with LGS

Today, Lundbeck Inc. presented positive data from its pivotal phase III study to determine the efficacy and safety profiles of the investigational compound clobazam as adjunctive therapy in treating seizures associated with Lennox-Gastaut syndrome.

6 Dec 2010

Seasonal light cycles can affect development of babies' specific brain function: Study

The season in which babies are born can have a dramatic and persistent effect on how their biological clocks function.

6 Dec 2010

Personal environment influences effects of genes and risk of disease

Personalized medicine centers on being able to predict the risk of disease or response to a drug based on a person's genetic makeup. But a study by scientists at Washington University School of Medicine in St. Louis suggests that, for most common diseases, genes alone only tell part of the story.

4 Dec 2010

Gene mutation can lead to different mental illnesses when influenced by same environmental factor

Male mice born with a genetic mutation that's believed to make humans more susceptible to schizophrenia develop behaviors that mimic other major psychiatric illnesses when their mothers are exposed to an assault to the immune system while pregnant, according to new Johns Hopkins research.

4 Dec 2010

AVMA condemns actions of animal rights activists against UCLA research neuroscientist

Citing its policy on the use of animals in research, testing and education, the American Veterinary Medical Association (AVMA) today condemned the recent actions of animal rights activists who have targeted a University of California research neuroscientist. The scientist's work includes the use of nonhuman primates to research biochemical factors that contribute to methamphetamine and tobacco addiction in adolescents, as well as to better understand cognitive problems that contribute to behavioral, speech and reasoning disabilities in schizophrenics.

2 Dec 2010

People with mental health diagnoses receives poor quality of preventive mass screening

Dr Alex Mitchell, of the Department of Cancer Studies and Molecular Medicine at the University of Leicester, led the study which has been published in the journal General Hospital Psychiatry. Dr Mitchell said preventive screening refers to population based medical tests such as mammography, colonoscopy, blood pressure testing or cholesterol levels to detect conditions such as cancer, diabetes or heart conditions. These screening programmes are typically administered widely in order to help with early detection or prevention and have been credited with improving outcomes of several key medical conditions.

2 Dec 2010

Cyrenaic announces results of CYR-101 Phase IIa clinical trial for schizophrenia

Cyrenaic Pharmaceuticals Inc. a private drug development company focused on the treatment of CNS disorders, today announced Phase IIa clinical results for CYR-101, its novel investigational drug for the treatment of schizophrenia. The results from the study showed that the drug alleviated the symptoms of the disease, including the negative and cognitive symptoms.

30 Nov 2010

Nine out of ten of all primary care centers in Sweden prescribe physical activity

Prescribing physical activity for the purpose of preventing and treating various conditions can now become a reality for healthcare professionals all over the world.

30 Nov 2010

Study finds gender difference in brain function of schizophrenics

Schizophrenia is a mental disorder that differs between the sexes in terms of age at onset, symptomatology, response to medication, and structural brain abnormalities. Now, a new study from the Universit- de Montr-al shows that there is gender difference between men and women's mental ability with women performing better than men.

20 Nov 2010

Ontario Brain Institute initiates new venture to help people with neurological disorders

Ontario took a major step to help the one million people in the province with neurological disorders and the 2.6 million Ontarians who will be affected by a neurological condition in their lifetime.

20 Nov 2010

Psychiatric hospitalization rate decreases among adults with schizophrenia treated with INVEGA SUSTENNA: Study

Schizophrenia is a chronic and disabling brain disorder that affects 1 percent of the U.S. population and results in substantial medical and societal costs, in particular from use of health-care resources. It also can have devastating health-related and social effects on people with the disease, their families and caregivers.

20 Nov 2010

Schizophrenia News and Research

Latest Schizophrenia News and Research

MDMA produces friendliness, playfulness, and loving feelings in laboratory setting

Access problems for psychiatric patients to Medicaid medication leads to increased hospital, emergency care

First genetic test on developing risk of Alzheimer's disease and heart attacks

Sunovion reports results of Latuda third phase 3 worldwide clinical trial for schizophrenia

Alkermes announces preliminary results from ALKS 33 Phase 2 study in alcohol dependence

Alexza Pharmaceuticals to meet with FDA to discuss CRL regarding its NDA for AZ-004

Expansion of newborn screening throws some families on a journey of great uncertainty

People suffering psychotic disorders 12 times more likely to commit suicide

Genentech announces Phase II study results of RG1678 for treatment of schizophrenia

Lundbeck reports positive phase III study data of clobazam in treating seizures associated with LGS

Seasonal light cycles can affect development of babies' specific brain function: Study

Personal environment influences effects of genes and risk of disease

Gene mutation can lead to different mental illnesses when influenced by same environmental factor

AVMA condemns actions of animal rights activists against UCLA research neuroscientist

People with mental health diagnoses receives poor quality of preventive mass screening

Cyrenaic announces results of CYR-101 Phase IIa clinical trial for schizophrenia

Nine out of ten of all primary care centers in Sweden prescribe physical activity

Study finds gender difference in brain function of schizophrenics

Ontario Brain Institute initiates new venture to help people with neurological disorders

Psychiatric hospitalization rate decreases among adults with schizophrenia treated with INVEGA SUSTENNA: Study

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Schizophrenia News and Research

Latest Schizophrenia News and Research

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in